Navigation Links
Neuland Labs Reports Financial Results For Fiscal Year 2012
Date:5/3/2012

HYDERABAD, India, May 3, 2012 /PRNewswire/ -- Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the 2012 fiscal year (FY) ended March 31, 2012.

"We are pleased to begin the new fiscal year with the successful closing of our rights offering, which has both strengthened the firm's equity and infused cash into operations to fuel growth.  We continue to see promise in all three Neuland business segments -- APIs, Contract Research and Manufacturing and Peptides, and we look forward to continued growth during the coming year," said Dr. D.R. Rao, Chairman and Managing Director of Neuland Labs. 

Revenues for FY 2012 were $88.07 million (4.48 billion INR*) compared to FY 2011 revenues of $78.04 million (3.97 billion INR*), an increase of 13%.  The increase in revenues primarily reflects gains in sales of the company's products and services from its API and Contract Research and Manufacturing businesses.

Neuland reported FY 2012 EBITDA of $9.50 million (483 million INR*), compared to EBITDA of $9.83 million (500 million INR*) in FY 2011.  The decrease in EBITDA primarily reflected higher costs for raw materials, energy and other inputs during the 2012 fiscal year.

After-tax profits in FY 2012 were $0.40 million (20 million INR*), compared to after-tax profits in FY 2011 of $1.00 million (51 million INR*).  The decrease in after-tax profits primarily reflects increases infinance costs and the impact of foreign exchange adjustments.

"We launched four new APIs for the generic market in the past year, which have all been successful in terms of our customers' ability to gain significant market share based on the strong pricing position and sustainable capacity our products make possible," commented Sucheth R. Davuluri, Chief Executive Officer of Neuland Labs.  "In addition, the company is focusing on reducing the costs of existing key products and increasing margins significantly in the current year.  For 2012-13, we are targeting an overall cost reduction equal to 4% of sales as a result of our planned reductions in cost of goods."

For a complete set of Neuland's FY 2012 and FY 2011 financial data, visit http://neulandlabs.com/about/financials.htmlNeuland Laboratories is listed on India's National Stock Exchange under the symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558 and the symbol Neuland.EO.* = Indian rupees

About Neuland Labs
For over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing.  The company is committed to research, supporting a state-of-the-art R&D operation.  Neuland Labs scientists have developed more than 300 processes from bench scale to commercial production and filed more than 400 drug master files worldwide.  Its manufacturing facilities are inspected and approved by the FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the FDA, TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and OHSAS 18001.  For more information, visit www.NeulandLabs.com 

Contacts:Neuland Laboratories Ltd.

US MediaNS Viswanathan

BLL Partners/Brandwidth SolutionsVice President- Finance

Barbara Lindheim+91 40 30211600

+1 212 584-2276 x 201nsviswanathan@neulandlabs.com

blindheim@bllbiopartners.com


'/>"/>
SOURCE Neuland Laboratories Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuland Labs Reports First Quarter Fiscal Year 2012 Financial Results
2. Neuland Labs Launches Expanded Peptide Manufacturing Capabilities at 22nd American Peptide Symposium
3. Neuland Labs Reports Financial Results for Fiscal Year 2011
4. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
5. GP Strategies Reports Strong First Quarter 2012 EPS of $0.23
6. Cardinal Health Reports Third-Quarter Results
7. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. CVS Caremark Reports Record First Quarter Results
11. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):